222 Introduction: 565 Participants and Methods: 966 Abstract Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD) and affects 1% of the population above 60 years old. Although PD commonly manifests with motor symptoms, a majority of patients with PD subsequently develop cognitive impairment which often progresses to dementia, a major cause of morbidity and disability. PD is characterized by α -synuclein accumulation that frequently associates with amyloid beta (Aβ) and tau fibrils, the hallmarks of AD neuropathologic changes; this cooccurrence suggests that onset of cognitive decline in PD may be associated with appearance of pathologic Aβ and/or tau. Recent studies have highlighted the appearance of the soluble form of the Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) receptor in CSF during development of AD. Given the known association of microglial activation with advancing PD, we investigated whether CSF and/or plasma sTREM2 increased with progression to PD dementia. We examined 165 participants consisting of 17 cognitively normal elderly, 45 PD patients with no cognitive impairment, 86 with mild cognitive impairment, and 17 with dementia. Stratification of subjects by CSF Aβ and tau levels revealed that CSF sTREM2
Introduction
Parkinson's disease (PD) affects 1% of the population above 60 years old (de Lau and Breteler, 2006) and is the most common neurodegenerative disease after Alzheimer's disease (AD). While PD is typically considered a disease of motor function, one in four patients meet criteria for mild cognitive impairment (MCI) at diagnosis (Muslimovic et al., 2005; Aarsland et al., 2009 ) and nearly 80% eventually develop dementia during the course of the disease (Aarsland et al., 2003; Hely et al., 2008; Cholerton et al., 2013) . These non-motor symptoms do not improve with dopamine enhancing therapies and contribute significantly to late morbidity, loss of quality of life, and mortality. Although at initial diagnosis, 6.5% of PD patients show abnormal CSF levels of Aβ 42 and tau (Marek et al., 2018) , at autopsy, 60-80% of PD subjects will have developed brain pathology consistent with AD, with prominent accumulation of amyloid plaques and/or tau containing neurofibrillary tangles (Tsuang et al., 2013; Dickson et al., 2018; Robinson et al., 2018) . Thus in a vast majority of patients with PD, AD pathophysiologic processes are initiated at some point after diagnosis. Progression of parkinsonism and cognitive decline are accelerated in individuals with AD and/or cerebrovascular disease (CVD) (Tsuang et al., 2013; Dickson et al., 2018; Buchman et al., 2019) . Identifying a biomarker that could help predict a change in cognitive function in PD would be a valuable tool for clinical management and outcome measure for clinical trials. Given the heterogeneous nature of PD, there is a significant unmet need for markers that could differentiate subgroups of PD patients that vary in rate of progression along cognitive and motor trajectories, or subgroups of PD patients with important differences in pathogenesis (Chen-Plotkin et al., 2018) .
Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor expressed on the surface of monocytes, neutrophils, macrophages, and brain microglia (Colonna, 2003) . Functionally, TREM2 plays a central role in phagocytosis of apoptotic neurons, misfolded proteins, and cellular debris (Neumann and Takahashi, 2007; Wang et al., 2016; Yeh et al., 2016) . TREM2 signaling also enhances microglial survival, proliferation, chemotaxis, and through effects on metabolism, inhibits the microglial proinflammatory response (Hamerman et al., 2006; Turnbull et al., 2006; Otero et al., 2009; Ulland et al., 2017; Parhizkar et al., 2019) .
Overexpression of TREM2 attenuates neuroinflammation and protects dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD (Ren et al., 2018) . In human genetic studies, the loss of function p.R47H variant of TREM2 is a risk allele for AD (Guerreiro et al., 2013; Jonsson et al., 2013) and sporadic PD (Benitez et al., 2013; Rayaprolu et al., 2013) .
The soluble form of TREM2 (sTREM2) is produced via the cleavage of membrane-bound TREM2 by disintegrin and metalloproteinase domain-containing protein (ADAM) family members, including ADAM10 and ADAM17 (Wunderlich et al., 2013; Kleinberger et al., 2014) , and by alternative splicing (Guerreiro et al., 2013) . CSF levels of sTREM2 are a sensitive marker of microglial activation and correlate with tau-mediated neuronal injury in AD (Kleinberger et al., 2014; Henjum et al., 2016; Heslegrave et al., 2016; Piccio et al., 2016; Suarez-Calvet et al., 2016a; Suarez-Calvet et al., 2016b; Suarez-Calvet et al., 2019) . In this cross-sectional retrospective multicenter study, we tested whether CSF and/or blood sTREM2 appeared during the progression of PD to PD with dementia, and whether it correlated with CSF concentrations of Aβ 1-42 , Aβ 1-40 , total tau, and phospho-tau p181 , or with cognitive status.
Materials and methods

Study population
Participants (N=165) were recruited from the Pacific Udall Center (PUC) cohort consisting of sites at Seattle (VA Puget Sound Health Care System/University of Washington) and Portland (Cholerton et al., 2013) and from the Stanford Movement Disorders Clinic. Participants were included if they were cognitively normal healthy adults or if they met United Kingdom Parkinson's Disease Society Brain Bank clinical diagnostic criteria for PD, had a cognitive diagnosis assigned (no cognitive impairment, MCI (Cholerton et al.) , PD dementia (Cholerton et al.) , and if they completed lumbar puncture. A full neuropsychological battery assessing multiple domains was given to assign a cognitive diagnosis. Participants from Stanford were defined as cognitively impaired if scores were ≥ 1.5 standard deviations below age-and education-matched normative values on at least two separate neuropsychological measures, regardless of domain (Hendershott et al., 2019) . The Pacific Udall Center assigned cognitive diagnoses at a clinical consensus conference and required evidence of subjective and observed cognitive decline. For all PD participants, cognitive impairment was further classified as PD-Dementia, as opposed to PD-MCI if the impairment was severe enough to interfere with daily activities (Emre et al., 2008) .
All study protocols were approved by Institutional 
Global cognitive function
Global cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) test (Nasreddine et al., 2005) . The MoCA is the most commonly used cognitive assessment in PD and has a high sensitivity and specificity for identifying MCI in PD (Hendershott et al., 2017) .
The MoCA is used in large multicenter PD studies because it assesses primary cognitive domains at risk in PD, has been validated in multiple languages, and requires substantially less time and training to properly administer and score than a full neuropsychological assessment (Chou et al., 2010) .
Plasma and CSF collection
For the Stanford University cohort, fasted plasma was collected within two weeks of lumbar puncture. For the two PUC cohorts, centers in Seattle and Portland performed CSF and plasma blood draws on the same morning. CSF samples were subjected to a maximum of two freezethaw cycles, as recommended by Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (Lewczuk et al., 2018) .
Measurement of AD CSF core biomarkers
The following cutoff values for abnormal CSF biomarkers were employed: ratio CSF Aβ 1-42 /Aβ 1-40 < 0.10, phospho-tau 181 > 40 pg/ml, and total tau > 456 pg/ml, as measured using Lumipulse G Assays (Fujirebio, Malvern, PA) on the LUMIPULSE G fully automated platform (Bayart et al., 2019; Paciotti et al., 2019) . CSF samples from all three cohorts were measured all together in one day by trained operators who were blinded to the clinical information. Samples were measured on the same day using the same reagents.
CSF and plasma sTREM2 measurement
Statistical analysis
CSF (Shapiro-Wilk normality test, W = 0.8499, P < 0.0001) and plasma sTREM2 (W = 0.2202, P < 0.0001) did not follow a normal distribution and were log 10 -transformed to approach the assumptions of Gaussian normal distribution. Therefore, all statistical analyses described in this study are performed with the log 10 -transformed values. Categorical variables were assessed by performing the chi-square test. Association of sTREM2 with continuous variables was evaluated using a linear regression model. Demographic parameters between groups were evaluated using one-way ANOVA followed by Tukey corrected post hoc pairwise comparisons (for parametric data) and Mann-Whitney U test or Kruskal-Wallis test followed by Dunn's corrected post hoc comparisons (for non-parametric data). To determine whether CSF and plasma sTREM2 differed among clinically-and biomarker-defined groups, Log 10 -transformed CSF sTREM2 levels were analyzed using ANCOVA with clinical diagnosis as fixed factor and age and gender as covariates. Tukey's multiple comparisons test was performed for post hoc testing. Receiver operating characteristic (ROC) curve analysis was performed to assess CSF sTREM2 in differentiating PD participants with abnormal CSF tau concentration from those with normal CSF tau concentration. Association between CSF sTREM2 and core AD CSF biomarker was assessed using linear mixed-effects model adjusting for age and gender as fixed effects and CSF sample freeze-thaw number as random effect. Association between CSF sTREM2 and MoCA score was assessed using a linear model adjusted for age, gender, years of education, and study site. Statistical tests were performed using GraphPad Prism software (GraphPad Inc, La Jolla, CA) and the freely available statistical software R (http://www.r-project.org/). All tests were two-sided and a significance level of α = 0.05 was adopted.
Data availability
The data that support the findings of this study are available from the corresponding author, upon request.
Results
Study participant characteristics
Demographic information for the study population is presented in Table 1 . The clinicallydefined diagnostic groups consisted of healthy cognitively unimpaired age-matched controls (Healthy Control), cognitively normal PD subjects (PD-Normal), PD subjects with mild cognitive impairment (PD-MCI) and PD subjects with dementia (PD-D). These groups differed in gender distribution (χ 2 = 16.44, df = 1, P < 0.0001), with a larger proportion of male subjects in the PD-MCI and PD-D groups. This is in line with previous data indicating that PD patients who are male are more likely to be cognitively impaired (Cholerton et al., 2018) . No differences were observed between any of the diagnostic groups for age (one-way ANOVA: F (3,161) = 2.526; P > 0.05) or disease duration as defined as time in years since diagnosis (Kruskal-Wallis χ 2 = 4.767, df = 3, P = 0.092). As expected, performance on the MoCA, a test sensitive to global cognition and executive function in PD (Hendershott et al., 2017) , differed between clinical diagnostic groups (Kruskal-Wallis chi-squared = 67.522, df = 3, P < 0.0001). While no significant difference was observed between Healthy Control and PD-Normal, the MoCA score was significantly lower in the PD-MCI (P < 0.001) and PD-D (P < 0.0001) groups. We observed significant differences in the off-medicine Movement Disorders Society-Unified PD Rating Scale motor part III (MDS-UPDRS) across PD diagnoses (Kruskal-Wallis test (χ 2 = 15.69, df=3, P = 0.0004), which confirmed equal motor symptom severity in the PD-Normal and PD-MCI groups (P > 0.05), but increased motor symptoms in the PD-D compared to both PD-Normal (P < 0.01) and PD-MCI (P < 0.001) groups. Finally, the percentage of APOE ε 4 carriers was not significantly different in any of the diagnostic groups (χ 2 = 0.419, P = 0.518).
Association between sTREM2 with demographic information
Overall, age was positively associated with CSF sTREM2 (β = +0.336, SE = 0.006, P < 0.0001) but not plasma sTREM2 (β = -0.064, SE = 0.016, P = 0.412). We observed no association between disease duration and CSF sTREM2 (β = +0.029, SE = 0.010, P = 0.714) or plasma sTREM2 (β = +0.0166, SE = 0.027, P = 0.534). Furthermore, compared to female participants, male participants showed significantly higher CSF sTREM2 (Mann-Whitney U = 1660, N=165, P < 0.0001) but not plasma sTREM2 (Mann-Whitney U = 2783, N = 165, P > 0.05). For these reasons, we included age and gender in our statistical models for CSF sTREM2. Including age and gender in statistical models evaluating plasma sTREM2 did not change the outcome of the analyses.
Baseline CSF and blood plasma sTREM2 levels in PD
We first determined whether CSF and plasma levels of sTREM2 differed in PD along the cognitive spectrum between PD-Normal, PD-MCI, and PD-D, compared to healthy age-matched controls. Log 10 -transformed CSF sTREM2 levels were analyzed using ANCOVA with clinical and cognitive diagnosis as fixed factor and age and gender, and study site as covariates. This revealed that CSF sTREM2 levels were significantly modulated in PD (One-way ANCOVA:
F (3,159) = 4.588; P = 0.004; Fig. 1A) with CSF sTREM2 significantly elevated in cognitively normal PD participants compared to healthy control subjects (Tukey's multiple comparisons test: P = 0.046). Higher concentrations of sTREM2 were observed in plasma compared to CSF overall, however, no differences were observed between PD-Normal, PD-MCI, and PD-D ( Fig.   1B ) (One-way ANCOVA: F (3,159) = 0.518; P = 0.671). Therefore, subsequent analyses focused on CSF sTREM2.
Heterogeneity in amyloid and tau co-pathologies in Parkinson's disease
CSF Aβ and tau concentrations can reveal biomarker-defined AD (Jack et al., 2018) , even within clinically-defined PD patient populations (van Steenoven et al., 2016) . Therefore, we used measurement of CSF amyloid and tau concentrations to stratify participants into one of five CSF biomarker-defined groups: 1) Controls with normal amyloid and tau (Controls); 2) PD with normal amyloid and tau [pure Lewy Body (LB) PD]; 3) PD with abnormal amyloid and normal tau (PD:Aβ+); 4) PD with both abnormal amyloid and tau (PD:Aβ+/Tau+); and 5) PD with normal amyloid but abnormal tau (PD:Tau+). Levels of CSF amyloid and tau biomarkers across each of the CSF biomarker-defined diagnostic groups are shown in Table 2 .
CSF sTREM2 is elevated in PD with abnormal CSF tau concentration
To determine the utility of a biomarker-defined diagnosis in PD, we next compared CSF sTREM2 expression across biomarker-defined groups ( Fig. 2A) . After adjusting for age and gender, we found that CSF sTREM2 was significantly different between the biomarker-defined groups (F 4,158 = 8.926, P < 0.0001). Post-hoc testing revealed no significant differences between healthy control, pure LB PD, or PD:Aβ+ groups. In contrast, CSF sTREM2 was significantly elevated in the PD:Aβ+/Tau+ group compared to control (P < 0.001), pure LB PD (P < 0.001), and PD Aβ+ groups (P = 0.011). CSF sTREM2 remained significantly elevated in the PD:Tau+ group, even in the absence of abnormal CSF Aβ, compared to the control (P < 0.001), pure LB PD (P = 0.002), and trended towards elevated relative to the PD:Aβ+ (P = 0.057) groups.
Receiver operating characteristic (ROC) curve analysis revealed that CSF sTREM2 could differentiate PD participants with abnormal CSF tau concentration (N=46) from those with normal CSF tau concentration (N=119; Fig. 2B) , with an area under curve (AUC) of 0.828 (95% confidence interval (CI) = 0.757-0.899).
CSF sTREM2 in biomarker-defined PD groups across clinical diagnosis
CSF sTREM2 concentration was determined for each PD patient subgroup stratified according to CSF biomarker profile. After adjusting for age and gender, CSF sTREM2 concentrations were significantly different between biomarker-defined groups within the diagnoses PD-Normal (F 3,39 = 4.415, P = 0.009), PD-MCI (F 3,80 = 6.626, P = 0.001, and PD-D (F 2,12 = 4.498, P = 0.035; (Fig.   3) . Post-hoc analysis using Tukey contrasts revealed that CSF sTREM2 level was significantly higher in the PD:Aβ+/Tau+ and PD:Tau+ subgroups compared to the pure LB PD subgroup in all three PD-Normal, PD-MCI, and PD-D diagnoses. This indicates that CSF sTREM2 is elevated in PD patient subgroups with abnormal CSF tau concentration, but not CSF Aβ concentration, before the onset of MCI or dementia.
Association between CSF sTREM2 and CSF Aβ and tau concentrations
We next studied the relationship between CSF sTREM2 and the core AD CSF biomarkers phospho-tau p181 , total tau, Aβ 1 -42 , and Aβ 1 -40 . We found that in the pooled group of participants, 
Discussion
Substantial biological heterogeneity underlies the clinical presentation and progression of PD and there is a significant need for markers that differentiate subgroups of PD patients in their rate of progression along cognitive and motor trajectories, or in the types of co-morbid disease (Chen-Plotkin et al., 2018) . We report here that CSF sTREM2 is increased in PD patient subgroups with abnormal CSF tau concentration, with or without abnormal CSF Aβ concentration, and that this increase precedes cognitive impairment.
Our observation that CSF sTREM2 is increased prior to cognitive symptoms in PD stages is similar to that seen in the progression to late-onset AD (Kleinberger et al., 2014; Henjum et al., 2016; Heslegrave et al., 2016; Piccio et al., 2016; Suarez-Calvet et al., 2016b; Suarez-Calvet et al., 2019) , and early-onset familial AD (Suarez-Calvet et al., 2016a) . In AD, the increase in CSF sTREM2 concentration occurs after pathological decrease in CSF Aβ 1-42 levels, and coincident with increased CSF tau concentration. In PD, we observed a similarly strong association between CSF sTREM2 and phospho-tau 181 and total tau concentrations, which are markers of neuronal and axonal cell injury and neurofibrillary tangles (Suarez-Calvet et al., 2019) . We show that the elevation of CSF sTREM2 levels could differentiate PD participants with or without abnormal CSF tau concentration with an area under the curve of 0.828 (CI = 0.757-0.899).
These results also suggest that CSF sTREM2 may serve as a general biomarker of neuronal injury across neurological diseases characterized by a neuroinflammatory component. Beyond PD and AD, CSF sTREM2 is also elevated in HIV-1 infection (Gisslen et al., 2019) , where high levels of hyperphosphorylated tau protein have been documented (Brew et al., 2005) . CSF sTREM2 concentration also is elevated in relapsing-remitting multiple sclerosis (MS), primary progressive MS, and other inflammatory neurological disease (OIND) subjects (Piccio et al., 2008) , and these forms of MS are also associated with tau pathology (Bartosik-Psujek and Stelmasiak, 2006; Anderson et al., 2008; Anderson et al., 2010; Jaworski et al., 2012) . We also found a positive association between CSF sTREM2 and Aβ concentrations across all diagnostic groups, an association previously observed in dementia patients (Henjum et al., 2018) .
sTREM2 is produced either from cleavage of surface-expressed TREM2 on brain microglia and parenchymal macrophages, or from alternative splicing in those cells; the relative proportion of these contributions is unknown, as it is not possible to estimate levels of surface TREM2 at this time in brain. If sTREM2 is generated mainly through cleavage of functional surface TREM2, that would indicate that the beneficial TREM2 immune response is in decline, heralding progression to full dementia. Indeed, the findings in this study and those in AD, where sTREM2 peaks at the MCI stage and then declines, may be consistent with the idea that compensatory anti-inflammatory and pro-phagocytic TREM2 responses become limiting, allowing diseasecausing processes to accelerate.
In plasma, we observed a 2.1-fold increase of sTREM2 concentration compared to CSF, however, no significant difference was observed in any of the PD subgroups. This is possibly due to the cross-sectional nature of this study and the high level of variance in plasma sTREM2.
Follow-up studies with longitudinal sampling may reduce the variance observed. For example, in a prospective longitudinal study, higher levels of sTREM2 in blood were associated with increased risk of developing dementia, AD, and vascular dementia in the general elderly Japanese population (Ohara et al., 2019) .
Finally, the finding that CSF sTREM2 is positively associated with MoCA score in PD participants with elevated CSF tau concentration is of interest. A putative neuroprotective association of CSF sTREM2 suggests an increase in functioning, surface expressed TREM2 in brain either before or at the time sTREM2 is elevated in CSF. A neuroprotective function of TREM2 signaling in microglia is supported by genome wide association studies (Guerreiro et al., 2013; Jonsson et al., 2013) and preclinical research in mouse models of AD Raha et al., 2017; Ulland et al., 2017; Cheng-Hathaway et al., 2018; Parhizkar et al., 2019) . A neuroprotective role of sTREM2 has been recently proposed in the 5xFAD mouse AD model where direct injection of sTREM2 protein or viral-mediated overexpression of sTREM2 in hippocampus was associated with a reduction of amyloid plaque load and a rescue of spatial memory and long-term potentiation deficits (Zhong et al., 2019) . It is possible that increasing CSF sTREM2 levels in advancing cognitive decline might reflect prior or ongoing TREM2 signaling that is being terminated by cleavage of the membrane bound TREM2 and release.
Further studies are warranted to better understand the temporal relationship between parenchymal microglial TREM2 expression and signaling and the appearance of the soluble form of TREM2.
In conclusion, we demonstrate that levels of CSF sTREM2 increase in PD patient subgroups with abnormal CSF tau concentration, with or without abnormal CSF amyloid concentration, and this increase is observed in cognitively normal and MCI PD subgroups. These findings suggest that CSF sTREM2 could serve as a surrogate biomarker of TREM2-mediated microglia function and neuronal injury in PD. 
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Figure 4:
Association between CSF sTREM2 and CSF Aβ and tau biomarkers. Significant association was observed between CSF sTREM2 levels and CSF total tau (A-C) and p-Tau181 (D-F) for all diagnostic groups. In no group did CSF sTREM2 associate with Aβ 1-42 (G-I).
Significant association was observed between CSF sTREM2 levels and CSF Aβ 1-40 for PD Cognitively Normal (J) and PD Dementia diagnoses (L), and trended towards significance in PD MCI (K). Associations between CSF sTREM2 and biomarkers were assessed using linear mixed-effects model with age and gender as fixed effects and freeze-thaw cycle number as random effect. Biomarker values were log-transformed to reduce skewness. Plotted is the 95% confidence band of the best-fit line from the linear regression. β estimates and P-values from the linear model are shown. CSF and plasma sTREM2 data were log-transformed and analyzed using a one-way ANCOVA with age and gender as co-variates, followed by post hoc multiple comparisons using Tukey contrasts. Log-transformed CSF sTREM2 data were analyzed using a one-way ANCOVA and were adjusted by gender and age followed by post hoc multiple comparisons using Tukey contrasts.
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